Hypoxia-preconditioned MiotEVs from bone marrow mesenchymal stem cells inhibit myocardial infarction-induced cardiac fibrosis.

ABSTRACT: Hypoxia-preconditioned bone marrow mesenchymal stem cell-derived mitochondrial extracellular vesicles (Hypoxia-BMSC MitoEVs) emerged as a novel therapeutic candidate for myocardial infarction (MI)-induced cardiac fibrosis. Here, we demonstrate that MitoEVs isolated from hypoxic BMSCs, rich in intact mitochondria and the RNA-binding protein Quaking (QKI), potently inhibited TGF-β1-driven myofibroblast activation in vitro by suppressing α-SMA and collagen expression while restoring mitochondrial oxidative phosphorylation and metabolic balance. In a murine MI model, systemic delivery of Hypoxia-BMSC MitoEVs attenuated cardiac fibrosis, reduced infarct size, and improved left ventricular function. Pharmacological inhibition of mitochondrial ATP synthase in MitoEVs similarly dimin

SUBMITTER: Nie J 

PROVIDER: S-EPMC12821231 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature